Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · April 04, 2022

Efficacy of Semaglutide in Aiding Weight-Loss and Lowering HbA1c in Individuals Previously on Another GLP1RA

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Injectable semaglutide and reductions in HbA1c and weight in the real-world in people switched from alternative glucagon-like peptide 1 receptor agonists
Diabetes Obes Metab 2022 Mar 23;[EPub Ahead of Print], T Crabtree, K Adamson, H Reid, D Barnes, S Sivappriyan, A Bickerton, IW Gallen, B Field, I Idris, R Ryder

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading